Research and development daily, WHO, includes Capu bionucleic acid testing kits on the emergency use list

Mercado/Pfizer SGLT2 inhibitor CV prognosis phase 3 reached the main endpoint; dexamethasone reduces mortality in patients with severe COVID-19; Lilly Verzenio significantly reduces risk of early breast cancer recurrence; Keytruda's second "unlimited cancer" indication is approvedWe focus on the latest developments in pharmaceutical research and development, to provide research and development personnel with timely and accurate information referenceMercado and Pfizer recently jointly presented the results of the Cardiovascular (CV) Prognosis III VERTIS CV trial at the 80th Scientific Meeting of the American Diabetes AssociationThe data showed that Steglatro showed non-adverse cardiovascular events in combination with placebo in combination with background standard care treatment, reaching the primary endpoint of the study, Pfizer released a phase 1 clinical study evaluating oral small molecule glucagon-like peptide 1 receptor agonists PF-06882961 in patients with type 2 diabetes, which showed significant results in reducing glucose levels and weight in patientstoday, a large large-scale recovery randomized control clinical trial in the UK announced that low-dose dexamethasone, in which it showed efficacy in reducing mortality in patients with severe inpatient COVID-19, Lilly recently announced that a randomized, double-blind, placebo-controlled Phase III trial for evaluating oral JAK1/JAK2 inhibitor baricitinib for the treatment of adult patients with neo-coronary pneumonia (COVID-19) has been enrolled in the first caseOn16, Lilly announced that the scheduled mid-term analysis results of the Phase III monarchE study had reached the primary endpoint, and that Verzenio's combined standard assisted endocrine therapy could significantly improve the survival of non-invasive diseases and significantly reduce the risk of recurrence or death compared to the use of standard assisted endocrine therapy aloneAstraZeneca recently presented a new subgroup analysis of the SGLT2 inhibitor-reducing drug Farxiga Milestone Cardiovascular Prognosis of DECLARE-TIMI 58 at the 80th Scientific Meeting of the American Diabetes AssociationThe results showed that Farxiga reduced the risk of rapid lysination rates in patients with type 2 diabetes who were associated with cardiovascular disease or at high risk of cardiovascular disease compared to placebosAXA Pharmaceuticals today announced that the company has completed its first patient administration in China in the second phase of a phase II clinical study of the treatment of chronic hepatitis B (CHB) in combination with The iAP inhibitor APG-1387On the 17th, Kepu Bio announced that the company's wholly-owned subsidiary Cap Chemical recently received a notice from the World Health Organization, learned that Cape Chemical research and development of the new coronavirus 2019-nCoV nucleic acid testkit (fluorescent PCR method) on June 15, 2020 was included in the WHO emergency use list, for other countries and regions to purchase, the FDA has accelerated approval of keytruda, a heavy PD-1 inhibitor developed by Mercado, according to the FDA's official website todayNon-removable or metastatic solid tumorpatients who are used to treat tumor mutations with high mutation loads and advances in disease after previous treatment do not need to consider the type of cancer16, Mersadong submitted in China Paboli Zhu singh singothetic fifth indication status changed to "in approval", is expected to be formally approved in the near futureKeytruda's approved indicationisis is a second-line treatment for esophageal cancer today, Novartis announced that the FDA has approved Cosentyx (Secukinumab, Commonly Known as Sukin sepsis), for the treatment of patients with active radiology-negative mid-axis spinal arthritis 16, Sanofi submitted in China Dupilumab injection (English product name: Dupixent) listing status changed to "in approval", is expected to be officially approved in China soon to be officially approved for the treatment of moderate to severe adhesion dermatitis recently, Nanjing Isaiu dating ginpyrosulphate pilates tablet imitation 4 categories of listing application into the administrative approval stage, is expected to be approved for listing in the near future on 17th, Qilu Pharmaceutical's new 4 generic drug Omexatan ester tablets were approved by the State Drug Administration for the treatment of hypertension, as if through consistency evaluation , Nanjing Changgao Pharmaceutical's pivastatin calcium tablet imitation 4 categories of listing application seiswell into the administrative approval stage, is expected to be approved in the near future today, Zhejiang Hangkang Pharmaceutical signed in accordance with the new 4 categories of injection of Parisib sodium listing application to obtain the approval of the State Drug Administration, as the same through the consistency evaluation, after Baiyu Pharmaceuticals, the second domestic product through the consistency evaluation of the enterprise on 17th, Xingqi eye drug 3 generic drug cyclosporine eye drops (II) was approved by the State Drug Administration for the treatment of dry eye disease On the 16th, Takeda and Neurocrine Biosciences announced a strategic partnership to jointly develop and commercially promote the early-to-mid-term research of new drug projects in the Takeda Psychotropic Drug Product Line Takeda gave neurocrine Biosciences exclusive licensing of seven of its psychotropic drugs, including three clinical phase projects for the treatment of schizophrenia, refractive depression, and sexual pleasure deficiency.